Free trade agreements and TRIPS-plus measures Online publication date: Tue, 03-Oct-2006
by Francisco Rossi
International Journal of Intellectual Property Management (IJIPM), Vol. 1, No. 1/2, 2006
Abstract: This paper examines the intellectual property clauses incorporated into recent bilateral and regional free trade agreements, particularly those signed by the USA with developing countries, and their implications for public health. The TRIPS-Plus provisions in these agreements are highlighted. These provisions are intended to put restrictions on the use of international non-proprietary names (INN), to extend patent duration beyond 20 years, to protect data of safety and efficacy with product exclusivity in the market, and finally to link patents to health registration. All these measures strengthen IP holders' rights, increasing the prices of new drugs and limiting room for public health authorities to provide necessary drugs to the population.
Online publication date: Tue, 03-Oct-2006
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email email@example.com